FRLN | Freeline Therapeutics Holdings plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.48 - 6.49
52 Week Range	2.1100 - 8.75
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,349
Average Volume	28,144
Shares Outstanding	4,357,950
Market Cap	28,283,096
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-08-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.57
Forward P/E Ratio	N/A
EPS	-11.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	152
Country	UK
Website	FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

FRLN's peers: ACHV, ANNX, ATAI, AVIR, IMMX, MNMD, NBTX, PHAT, RCUS, RXRX, RZLT, SPRY

*Chart delayed

Analyzing fundamentals for FRLN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see FRLN Fundamentals page.

Watching at FRLN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on FRLN Technicals page.